Publisher Correction: Structural basis for the inhibition of HTLV-1 integration inferred from cryo-EM deltaretroviral intasome structures

Barski, M.S.; Vanzo, Teresa; Zhao, Xue Zhi; Smith, Steven J.; Ballandras-Colas, Allison; Cronin, Nora; Pye, V.E.; Hughes, Stephen H.; Burke, Terrence R.; Cherepanov, Peter; Maertens, Goedele N.

doi:10.1038/s41467-021-26243-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These structures allowed us to use RAL-binding cavities consisting of the prototype foamy virus (PFV) or Simian T-lymphotropic virus 1 (STLV-1) IN protein, viral DNA, and catalytic metal cations. INSTI-binding models can substitute the HIV intasome for the PFV or STLV-1 intasome ( 34 , 35 ), and H-RAL-binding models were generated based on the templates in which RAL binds to the PFV or STLV-1 intasome. As previously reported ( 32–34 ), the interaction of RAL with the binding cavity of the IN intasome dislocates the terminal 3′ nucleotide of the viral DNA and appears to inhibit metal cation (Mn 2+ or Mg 2+ )-dependent activities (Figs.…”

Section: Resultsmentioning

confidence: 99%

Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity

Nakamura,

Okumura,

Takamune

et al. 2023

PNAS Nexus

View full text Add to dashboard Cite

Raltegravir (RAL), an HIV-1 integrase inhibitor, has been administered as part of antiretroviral therapy (ART). Studies in patients with HIV-1 have shown high variability in the pharmacokinetics of RAL, and in healthy volunteers, co-administration of proton pump inhibitors has been shown to increase the plasma RAL concentrations. Here, we found that RAL containing a 1,3,4-oxadiazole ring is converted to a hydrolysis product (H-RAL) with a cleaved 1,3,4-oxadiazole ring at pH 1.0 and 13.0 conditions in vitro, thereby reducing the anti-HIV activity of the drug. The inclusion of cyclodextrins (beta-cyclodextrin [βCD], random methyl-βCD [RAM-βCD], and hydroxypropyl-βCD [HP-βCD]) can protect RAL from pH-induced changes. The conversion of RAL to H-RAL was detected by using various mass spectrometry analyses. The chromatogram of H-RAL increased in a time-dependent manner similar to another 1,3,4-oxadiazole-containing drug, zibotentan, using high-performance liquid chromatography. Oral bioavailability and target protein interactions of H-RAL were predicted to be lower than those of RAL. Moreover, H-RAL exhibited significantly reduced anti-HIV-1 activity, whereas combinations with βCD, RAM-βCD, and HP-βCD attenuated this effect in cell-based assays. These findings suggest that βCDs can potentially protect against the conversion of RAL to H-RAL under acidic conditions in the stomach, thereby preserving the anti-HIV-1 effect of RAL. Although clinical trials are needed for evaluation, we anticipate that protective devices such as βCDs may improve the pharmacokinetics of RAL, leading to better treatment outcomes, including reduced dosing, long-term anti-HIV-1 activity, and deeper HIV-1 suppression.

show abstract

Section: Resultsmentioning

confidence: 99%